Therapeutic Targets of FDA-Approved Immunotherapies in Oncology
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-319-70622-1_2
Reference74 articles.
1. Ascierto, P. A., Chiarion-Sileni, V., Muggiano, A., Mandala, M., Pimpinelli, N., Del Vecchio, M., Rinaldi, G., Simeone, E., & Queirolo, P. (2014). Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy, 26, 193–201.
2. Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical Cancer Research, 21, 687–692.
3. Bersanelli, M., Buti, S., Camisa, R., Brighenti, M., Lazzarelli, S., Mazza, G., & Passalacqua, R. (2014). Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel), 6, 2035–2048.
4. Bonnem, E. M. (1991). alpha Interferon: The potential drug of adjuvant therapy: Past achievements and future challenges. European Journal of Cancer, 27(Suppl 4), S2–S6.
5. Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England Journal of Medicine, 373, 123–135.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bacterial Extracellular Vesicles: Potential Therapeutic Applications, Challenges, and Future Prospects;Journal of Basic Microbiology;2024-08-15
2. Bacterial extracellular vesicle applications in cancer immunotherapy;Bioactive Materials;2023-04
3. Cancer Immunotherapy: Diverse Approaches and Obstacles;Current Pharmaceutical Design;2022-08
4. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies;Frontiers in Immunology;2021-09-07
5. Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer Types;2019-08-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3